News

Deal Announcements

Allakos Adds $10 Million Venture Capital Funding

Wednesday, October 1, 2014 5:30:00 AM PDT | VentureDeal
   San Carlos, California  --  Biotechnology company Allakos has secured $10 million in new venture capital funding, according to a company statement.

Allakos is developing what it calls "first in class antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology."

Investors in the financing included Novo Ventures, Alta Partners, RiverVest Venture Partners and Roche Venture Fund.

The company said it would use the additional funding to advance to programs "towards meaningful near-term milestones."

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1